BridgeBio Pharma’s Acoramidis Phase 3 trial in ATTR-CM hits primary endpoint

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a  commercial-stage biopharmaceutical company specializing in genetic diseases and cancers, announced that the Phase 3 ATTRibute-CM study of acoramidis has ... Read More